About The coalition for 21st century medicine
The Coalition for 21st Century Medicine: Revolutionizing Healthcare through Innovative Diagnostic Tests
The healthcare industry is constantly evolving, and with the advent of new technologies, it has become increasingly important to ensure that patients have access to high-quality diagnostic tests. The Coalition for 21st Century Medicine (C21) is a non-profit organization that aims to revolutionize healthcare by advocating for innovative diagnostic tests that can improve patient outcomes.
Founded in 2011, C21 brings together stakeholders from across the healthcare industry, including diagnostic test developers, clinical laboratories, patient advocacy groups, and healthcare providers. The organization's mission is to promote policies that support the development and adoption of innovative diagnostic tests.
One of C21's primary goals is to ensure that patients have access to personalized medicine. Personalized medicine involves tailoring medical treatments based on an individual's unique genetic makeup. This approach can lead to more effective treatments with fewer side effects.
To achieve this goal, C21 advocates for policies that support the development of companion diagnostics - tests that are used in conjunction with specific drugs or therapies. Companion diagnostics can help identify which patients are most likely to benefit from a particular treatment.
C21 also works closely with regulatory agencies such as the FDA (Food and Drug Administration) and CMS (Centers for Medicare & Medicaid Services) to ensure that innovative diagnostic tests are approved quickly and efficiently. The organization advocates for policies that streamline the regulatory process while maintaining rigorous standards for safety and efficacy.
In addition to its advocacy work, C21 also provides educational resources on innovative diagnostic testing. The organization hosts webinars and conferences where stakeholders can learn about new developments in this rapidly evolving field.
C21 has been instrumental in advancing several key policy initiatives related to innovative diagnostic testing. For example, the organization played a key role in advocating for changes to Medicare reimbursement policies related to molecular pathology testing - a type of test used in cancer diagnosis and treatment planning.
Thanks in part to C21's advocacy efforts, Medicare now provides more appropriate reimbursement for these tests, which has helped to ensure that patients have access to the latest diagnostic technologies.
C21 has also been a vocal advocate for policies that support the development of next-generation sequencing (NGS) - a powerful tool used in genetic testing. The organization has worked with regulatory agencies and other stakeholders to develop guidelines for NGS testing and ensure that it is covered by insurance.
Overall, C21 is an important voice in the healthcare industry when it comes to advocating for innovative diagnostic tests. By bringing together stakeholders from across the industry and working closely with regulatory agencies, the organization is helping to ensure that patients have access to cutting-edge medical technologies that can improve their health outcomes.